Christina Gant
Family · Sioux Falls, SDNPI 1285732479
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$583
- AstraZeneca$309
- Daiichi Sankyo Inc.$253
- Novartis$217
- E.r. Squibb & Sons, L.L.C.$141
- Bristol Myers Squibb$119
- plus $881 from 25 others
What the payments were for
- Food & beverage$2,34194%
- Education$1626%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 24 | $583 |
| AstraZeneca(2 entities) | 6 | $309 |
| Daiichi Sankyo Inc. | 21 | $253 |
| Novartis | 11 | $217 |
| E.r. Squibb & Sons, L.L.C. | 6 | $141 |
| Bristol Myers Squibb | 7 | $119 |
| Pfizer | 5 | $89 |
| Pharmaessentia USA Corporation | 4 | $66 |
| Seagen Inc. | 1 | $65 |
| Gilead(2 entities) | 4 | $63 |
| Incyte Corporation | 3 | $62 |
| Mirati Therapeutics, Inc. | 3 | $55 |
| Merck | 3 | $53 |
| Beigene USA, Inc. | 3 | $52 |
| Eisai Inc. | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Immunogen, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $20 |
| Geron Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Amgen | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$124
How this compares
$2,503 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 36 | $402,212 |
| ImbruvicaIbrutinib | 16 | $255,342 |
| RevlimidLenalidomide | 13 | $228,811 |
| VerzenioAbemaciclib | 15 | $219,685 |
| EliquisApixaban | 32 | $19,874 |
| Potassium Chloride | 33 | $818 |
| Oxycodone Hcl | 25 | $688 |
| Doxycycline Hyclate | 25 | $460 |
| Anastrozole | 36 | $460 |
| Ondansetron OdtOndansetron | 27 | $383 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $364 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $328 |
| Prochlorperazine Maleate | 17 | $188 |
| Levothyroxine Sodium | 24 | $128 |
| Triamcinolone Acetonide | 12 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $62 | $402,21236 claims |
| Bristol Myers SquibbRevlimid | $119 | $228,81113 claims |
| Lilly USA, LLCVerzenio | $19 | $219,68515 claims |
| PfizerEliquis | $89 | $19,87432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.
Other family in Sioux Falls
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Michelle VanhoveSioux Falls$7K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Megan MoedingSioux Falls$5K
- Kari WestenkirchnerSioux Falls$4K
- Brooke MunkSioux Falls$4K
- Rebekka KlemmeSioux Falls$4K
- Jordyn HoferSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.